Pakistan has secured $629.5 million in commercial agreements through a two-day pharmaceutical business conference with China, marking one of the largest sector-specific engagements between the two nations. Federal Minister for National Health Services Mustafa Kamal announced the figures during a press conference on Wednesday, framing the event as a critical step toward reshaping the country's drug manufacturing landscape. Main Developments The conference brought together 240 Chinese delegates from 140 companies and 430 Pakistani delegates from 210 local firms, generating 340 bilateral business meetings. These meetings resulted in 22 binding commercial agreements worth $629.5 million and 84 memoranda of understanding valued at approximately $800 million, many of which are expected to evolve into formal investment deals. Signed agreements span six strategic sub-sectors: active pharmaceutical ingredients (APIs), local vaccine production, clinical trials, generic formulations and injectables, and medical devices manufacturing. Eight agreements focus on vaccine production alone, while another eight target medical devices. Read also: Why Pakistan's Tax Disputes Are Going Fully Digital To maximize outcomes, the Ministry of National Health Services arranged six weeks of virtual business matchmaking before the conference, ensuring companies arrived with advanced discussions rather than initial introductions. Kamal emphasized that the government prioritizes legally binding commercial agreements over MoUs, aiming for tangible investments, technology transfer, and job creation. Background Pakistan currently imports all 13 vaccines used in its national immunization program, despite producing nearly 85 percent of its pharmaceutical products locally. The country imports approximately 95 percent of the raw materials—active pharmaceutical ingredients—needed to manufacture medicines, creating a critical dependency. The government has recently approved a National Local Vaccine Production Policy, the first such framework in Pakistan's history, designed to enable domestic vaccine manufacturing. This policy aligns with broader reforms at the Drug Regulatory Authority of Pakistan (DRAP), where about 85 percent of regulatory processes have been digitized, reducing processing times and improving transparency. Why It Matters With a population exceeding 250 million, Pakistan's reliance on imported medicines and vaccines poses both economic and strategic vulnerabilities. Strengthening domestic pharmaceutical manufacturing can reduce import bills, improve health security during global supply disruptions, and create skilled employment in a growing industry. The digitization of DRAP processes—such as medical device registration now completed in 20 days instead of years—signals improved ease of doing business, which could attract further foreign investment. Kamal stressed that highlighting such achievements restores confidence in Pakistan's economy and investment potential amid ongoing challenges. What's Next The government plans to pursue several strategic priorities jointly with Chinese partners, including developing Pakistan's clinical trials ecosystem, promoting traditional Chinese medicine, establishing vocational training programs for the pharmaceutical workforce, and boosting local API production. The 84 MoUs signed during the conference are expected to mature into formal investment agreements, though their conversion rate remains to be seen. Kamal acknowledged coordinated efforts from the Embassy of Pakistan in Beijing, DRAP, the Trade Development Authority of Pakistan, the Board of Investment, and other agencies, signaling continued inter-agency collaboration to sustain momentum from the conference.